Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer-Reference-Cited by-同舟云学术

Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer

Published:2017-03-19 Issue:5 Volume:83 Page:1143-1145
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Aminkeng Folefac¹²,Ross Colin J. D.³,Rassekh Shahrad R.²⁴,Rieder Michael J.⁵,Bhavsar Amit P.³^ORCID,Sanatani Shubhayan²,Bernstein Daniel⁶,Hayden Michael R.¹²⁷,Amstutz Ursula⁸,Carleton Bruce C.²⁹

Affiliation:

1. Centre for Molecular Medicine and Therapeutics, Department of Medical GeneticsUniversity of British Columbia Vancouver British Columbia Canada

2. BC Children's Hospital Research InstituteUniversity of British Columbia Vancouver British Columbia Canada

3. Faculty of Pharmaceutical SciencesUniversity of British Columbia Vancouver British Columbia Canada

4. Division of Pediatric Hematology/Oncology/BMT, Department of PediatricsUniversity of British Columbia Vancouver British Columbia Canada

5. Department of PediatricsUniversity of Western Ontario London Ontario Canada

6. Department of Pediatrics, Division of CardiologyStanford University Stanford California USA

7. Teva Pharmaceutical Industries Petach Tikva Israel

8. University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern Switzerland

9. Division of Translational Therapeutics, Department of PediatricsUniversity of British Columbia Vancouver British Columbia Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13218

Reference17 articles.

1. Genetic determinants of anthracycline cardiotoxicity – ready for the clinic?

2. Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

3. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

4. Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children

5. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience;Biomedicine & Pharmacotherapy;2024-05

2. Anthracycline Toxicity: Light at the End of the Tunnel?;Annual Review of Pharmacology and Toxicology;2024-01-23

3. Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs;Antioxidants;2023-07-03

4. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients;British Journal of Clinical Pharmacology;2023-01-27

5. Preventing Anthracycline-Induced Cardiotoxicity Using Functional Genomics and Human-Induced Pluripotent Stem Cell–Derived Cardiomyocytes;Circulation;2022-01-25